On. Arch Virol 2007, 152(three):553?63. 13. Meyer C, Dewane J, Kerns A, Haberthur K, Barron A, Park B, Messaoudi I: Age and immune status of rhesus macaques impact simian varicella virus gene expression in sensory ganglia. J Virol 2013, 87:8294?306. 14. Deshmane SL, et al: Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009, 29(six):313?26. 15. Yamashita U, Kuroda E: Regulation of macrophage-derived chemokine (MDC, CCL22) production. Crit Rev Immunol 2002, 22(two):105?14. 16. Bernhagen J, et al: MIF is actually a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 2007, 13(five):587?96. 17. Liu MT, et al: Expression of Mig (monokine induced by interferongamma) is very important in T lymphocyte recruitment and host defense following viral infection from the central nervous system. J Immunol 2001, 166(three):1790?795. 18. Maurer M, von Stebut E: Macrophage inflammatory protein-1. Int J Biochem Cell Biol 2004, 36(10):1882?886. 19. Liu MT, et al: The T cell chemoattractant IFN-inducible protein 10 is crucial in host defense against viral-induced neurologic disease. J Immunol 2000, 165(five):2327?330. 20. Griffiths-Johnson DA, et al: The chemokine, eotaxin, activates guinea-pig eosinophils in vitro and causes their accumulation in to the lung in vivo.4,6-Dimethyl-1H-indole supplier Biochem Biophys Res Commun 1993, 197(three):1167?172. 21. Boehm U, et al: Cellular responses to interferon-g. Annu Rev Immunol 1997, 15:749?95. 22. Esposito E, Cuzzocrea S: TNF-alpha as a therapeutic target in inflammatory diseases, ischemia-reperfusion injury and trauma. Curr Med Chem 2009, 16(24):3152?167. 23. Hirano T, et al: Biological and clinical aspects of interleukin six. Immunol Currently 1990, 11(12):443?49. 24. Liao W, Lin JX, Leonard WJ: Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 2013, 38(1):13?5. 25. Fehniger TA, Caligiuri MA: Interleukin 15: biology and relevance to human disease. Blood 2001, 97(1):14?2. 26. Arend WP, et al: Interleukin-1 receptor antagonist: part in biology. Annu Rev Immunol 1998, 16:27?5. 27. Moore KW, et al: Interleukin-10. Annu Rev Immunol 1993, 11:165?90.10504-60-6 supplier 28.PMID:23357584 Welte K, et al: Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci USA 1985, 82(5):1526?530.29. Scott P: IL-12: initiation cytokine for cell-mediated immunity. Science 1993, 260(5107):496?97. 30. Carpenter G, Cohen S: Epidermal development issue. J Biol Chem 1990, 265(14):7709?712. 31. Yu PJ, et al: Basic fibroblast development issue (FGF-2): the higher molecular weight forms come of age. J Cell Biochem 2007, one hundred(5):1100?108. 32. Warn R: Growth aspects. A scattering of things. Curr Biol 1994, 4(11):1043?045. 33. Byrne AM, Bouchier-Hayes DJ, Harmey JH: Angiogenic and cell survival functions of vascular endothelial growth aspect (VEGF). J Cell Mol Med 2005, 9(four):777?94. 34. Pitcher CJ, et al: Development and homeostasis of T cell memory in rhesus macaque. J Immunol 2002, 168(1):29?3. 35. Nagaike K, et al: Cloning from the varicella-zoster virus genome as an infectious bacterial artificial chromosome in Escherichia coli. Vaccine 2004, 22(29?0):4069?074. 36. Tischer BK, et al: A self-excisable infectious bacterial artificial chromosome clone of varicella-zoster virus allows analysis of the important tegument protein encoded by ORF9. J Virol 2007, 81(23):13200?3208. 37. Yoshii H, et al: Cloning of full length genome of varicella-zoster virus vaccine st.